Maze Therapeutics (MAZE) CSBO reports option grants and stock sales

Rhea-AI Filing Summary

Maze Therapeutics, Inc. chief business and strategy officer Atul Dandekar reported a mix of equity awards, option exercise, and share sales. He received a grant of 38,000 stock options and 19,000 restricted stock units, each at an exercise or acquisition price of $0.00 per share.

On February 27, 2026, he exercised 7,500 stock options at $10.42 per share to acquire 7,500 shares of common stock, then sold 3,739 shares at a weighted average price of $45.134 and 3,761 shares at $45.7238. The sales were made under a Rule 10b5-1 trading plan adopted on September 29, 2025.

Following these transactions, he directly held 10,503 shares of common stock, 59,143 stock options and 19,000 restricted stock units. The new option award vests in 1/48 increments monthly starting April 1, 2026, while the RSUs vest in four annual tranches beginning March 1, 2027.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dandekar Atul

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CSBO

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		M(1)		7,500	A	$10.42	18,003	D
Common Stock	02/27/2026		S(1)		3,739	D	$45.134(2)	14,264	D
Common Stock	02/27/2026		S(1)		3,761	D	$45.7238(3)	10,503	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.42	02/27/2026		M(1)			7,500	(4)	04/11/2031	Common Stock	7,500	$0	59,143	D
Stock Option (Right to Buy)	$45.61	03/02/2026		A		38,000		(5)	03/01/2036	Common Stock	38,000	$0	38,000	D
Restricted Stock Units	(6)	03/02/2026		A		19,000		(7)	(8)	Common Stock	19,000	$0	19,000	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.55 to $45.54 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.55 to $46.02 per share, inclusive.

4. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.

5. The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date.

6. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

7. The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date.

8. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Atul Dandekar report for Maze Therapeutics (MAZE)?

Atul Dandekar reported new equity awards, an option exercise, and share sales. He received 38,000 stock options and 19,000 restricted stock units, exercised 7,500 options into common stock, and sold 7,500 shares in two tranches under a pre-arranged Rule 10b5-1 trading plan.

How many Maze Therapeutics shares did Atul Dandekar sell and at what prices?

He sold 7,500 Maze Therapeutics common shares in total. One block of 3,739 shares sold at a weighted average of $45.134 per share, and another 3,761 shares sold at a weighted average of $45.7238 per share, across multiple trades within stated price ranges.

What new equity awards did Maze Therapeutics grant Atul Dandekar in this Form 4?

Maze Therapeutics granted him 38,000 stock options and 19,000 restricted stock units. The options were issued with a $0.00 exercise price and vest monthly over 48 months, while the RSUs vest in four equal annual installments starting March 1, 2027, subject to continued service.

How do the new Maze Therapeutics stock options granted to Atul Dandekar vest?

The 38,000 Maze Therapeutics stock options vest in equal monthly installments. Specifically, 1/48 of the award vests each month, with the first tranche vesting on April 1, 2026, contingent on Atul Dandekar’s continued service to the company on each vesting date.

What is the vesting schedule for Atul Dandekar’s new Maze Therapeutics RSUs?

The 19,000 restricted stock units vest over four years. One quarter of the award vests on March 1, 2027, and the remaining three quarters vest on each one-year anniversary of that date, assuming his continued service to Maze Therapeutics at each vesting date.

How many Maze Therapeutics shares and awards does Atul Dandekar hold after these transactions?

After the reported transactions, he directly holds 10,503 Maze Therapeutics common shares. He also holds 59,143 stock options and 19,000 restricted stock units, reflecting both previously outstanding awards and the new grants disclosed in this Form 4 filing.